Cargando…

Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)

BACKGROUND: Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited. METHODS: This real world, cross-sectional s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribi, Karin, Thürlimann, Beat, Schär, Corinne, Dietrich, Daniel, Cathomas, Richard, Zürrer-Härdi, Ursina, von Briel, Thomas, Anchisi, Sandro, Bohanes, Pierre, Blum, Veronika, von Burg, Philippe, Mannhart, Meinrad, Caspar, Clemens B., von Moos, Roger, Mark, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893880/ https://www.ncbi.nlm.nih.gov/pubmed/33607966 http://dx.doi.org/10.1186/s12885-021-07903-8

Ejemplares similares

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
por: Mark, Michael, et al.
Publicado: (2019)

Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
por: Hayoz, Stefanie, et al.
Publicado: (2023)

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
por: Vetter, Marcus, et al.
Publicado: (2022)

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
por: Blum, David, et al.
Publicado: (2012)

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
por: König, D., et al.
Publicado: (2022)

P268 Impact of the 2020 COVID-19 lockdown in Switzerland on physical activity in patients with early breast cancer under aromatase-inhibitor therapy. A subanalysis of the SAKK 95/17 WISE trial
por: Hoefnagels, N., et al.
Publicado: (2023)

Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study
por: Varga, Zsuzsanna, et al.
Publicado: (2015)

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
por: Rochlitz, Christoph, et al.
Publicado: (2016)

1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
por: Joerger, M., et al.
Publicado: (2021)

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
por: Bratic Hench, Ivana, et al.
Publicado: (2019)

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
por: Joerger, Markus, et al.
Publicado: (2022)

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
por: Eppenberger-Castori, Serenella, et al.
Publicado: (2020)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
por: Joerger, M., et al.
Publicado: (2020)

Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
por: von Moos, Roger, et al.
Publicado: (2013)

Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects
por: Herrmann, Christian, et al.
Publicado: (2021)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland
por: Herrmann, Christian, et al.
Publicado: (2015)

Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
por: Hofheinz, Ralf-Dieter, et al.
Publicado: (2022)

Appropriateness of bone density measurement in Switzerland: a cross-sectional study
por: Zechmann, Stefan, et al.
Publicado: (2018)

Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada
por: Briel, Matthias, et al.
Publicado: (2021)

Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies
por: Herrmann, Christian, et al.
Publicado: (2018)

Augmented wealth in Switzerland: the influence of pension wealth on wealth inequality
por: Kuhn, Ursina
Publicado: (2020)

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer
por: Mamot, Christoph, et al.
Publicado: (2023)

The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients
por: Clough-Gorr, Kerri M, et al.
Publicado: (2013)

Discontinuation and non-publication of randomised clinical trials supported by the main public funding body in Switzerland: a retrospective cohort study
por: Amstutz, Alain, et al.
Publicado: (2017)

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2019)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
por: Pestalozzi, Bernhard C., et al.
Publicado: (2017)

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
por: Brune, Magdalena M., et al.
Publicado: (2021)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
por: Fürstenberger, G, et al.
Publicado: (2006)

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe
por: Body, Jean-Jacques, et al.
Publicado: (2018)

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries
por: von Moos, Roger, et al.
Publicado: (2017)

Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
por: Varga, Zsuzsanna, et al.
Publicado: (2019)

Incidence, Treatment and Outcome of Patients with Retroperitoneal Soft-Tissue Sarcoma in Switzerland 2005–2015: A Population-Based Analysis
por: Willburger, Johanna C. F., et al.
Publicado: (2021)

Small Area Variation of Adherence to Clinical Recommendations: An Example from Switzerland
por: Gruebner, Oliver, et al.
Publicado: (2022)

Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom
por: Qian, Yi, et al.
Publicado: (2018)

Researches on Bone-Absorption and Giant Cells
por: Rustizky, J. Von
Publicado: (1874)

Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
por: Zweifel, Martin, et al.
Publicado: (2017)

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study †
por: Genta, Sofia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d3qaue8ka44oe7vp600mohvjqf